Shin Nippon Biomedical Laboratories, Ltd. (JP:2395) has released an update.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Shin Nippon Biomedical Laboratories reported a 5.3% increase in revenue for the six months ending September 2024, reaching 12,508 million yen, despite a significant drop in operating profit by 96.6%. The company’s net assets grew to 36,453 million yen, although the equity ratio decreased to 40.9%. Dividends for the fiscal year are forecasted to remain stable at 50 yen per share.
For further insights into JP:2395 stock, check out TipRanks’ Stock Analysis page.